Recently, the questions of the limited opportunities for measurement of the subjective and often subclinical visual dysfunction are very topical. NEI-VFQ, the questionnaire of the National Eye Institute in the USA and VFQ-25, its short version (25-item Vision Function Questionnaire) are validated for visual-specific assessment of the quality of life of multiple sclerosis (MS) patients. MSVQ-7, a specific 7-item MS Vision Questionnaire is proposed, too. The authors used the VFQ-25 translated into Bulgarian, the MSVQ-7 and their correlation with the binocular visual acuity. These questionnaires were administered to 108 MS patients without history of optic neuritis and after optic neuritis as well registered in the MS Centre in Varna and to 30 healthy subjects. There was a statistically significant difference (p<0,0001) between MS patients and controls in all sub-scales and in the overall results from VFQ-25. The analysis of MSVQ-7 showed a statistically significant difference between the answers of question Nos 1, 2, 3 and 5 p<0,001 to p=0,015). The correlation of the results from VFQ-25 and the binocular visual acuity was moderate (Spearman's r=0,6; <0,01). The application of questionnaires for assessment of visual function may contribute to the identification of less known and sought subclinical visual dysfunctions that appear in normal visual acuity. Our data confirm the possible usage of VFQ-25 and MSVQ-7 for effective measurement of the subjective visual deficit in MS diagnosis.
Ashwor th, B. , P. A. Aspin al l , J. D. Mitchell. Visual function in multiple sclerosis.- Doc. Ophthalmol., 73, 1989, No 3, 209-224.
Balcer , L. J., M. L. Baier , A. M. Kunkle, et al. Self-reported visual dysfunction in multiple sclerosis: results from the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25).- Mult. Scler., 6. 2000, 382-385.
Balcer , L. J. Clinical outcome measures for research in multiple sclerosis.- J. Neuroophthalmol., 21, 2001, No 4, 296-301.
Col e , S. R., R. W. Beck, P. S. Moke, et al. The National Eye Institute Visual Function Questionnaire (NEI-VFQ): experience of the ONTT.- Invest. Ophthalmol. Vis. Sei., 41, 2000, 1017-1021.
Fischer , J. S., N. G. LaRocca, D. M. Mi l le r , P. G. Ritvo, H. Andrews , D. Paty . Recent developments in the assessment of quality of life in multiple sclerosis.- Mult. Scler., 5, 1999, 251-259.
Kupersmith, M. J., J. I. Nelson, W. H. Sei ple, et al. The 20/20 eye in multiple sclerosis.- Neurology, 33, 1983, 1015-1020.
Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).- Neurology, 33, 1983, 1444-1452.
Lycke, J., P. O. Tollesson, L. Frisen. Asymptomatic visual loss in multiple sclerosis.-J. Neurol., 248, 2001, No 12, 1079-1086.
Ma, S-L., J. A. Shea, S. L. Galetta, et al. Self-reported visual dystunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire.- Am. J. Ophthalmol., 133, 2002, No 5, 686-692.
Mangione, C. M. The National Eye Institute 25-Item Visual Function Questionnaire-scoring algorithm. 1997.
Mangione , C. M. , S. Berry , K. Spritzer, et al . Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons.- Arch. Ophthalmol., 116, 1998, 227-233.
Mangione, C. M. , P. P. Lee, J. Pitts , P. Gutierrez , S. Berry , R. D. Hays, for the NEI-VFQ Field Test Investigators. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ).- Arch. Ophthalmol., 116, 1998, 1496-1504.
Mangione, C. M. , P. P. Lee , P. R. Gutierez, K. Spr i tzer , S. Berry , R. D. Hays . Development of the 25-item National Eye Institute Visual Function Questionnaire.- Arch. Ophthalmol., 119, 2001, No 7, 1050-1058.
McDonald, W. I., D. Barnes . The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system.- J. Neurol. Neurosurg. Psychiat., 55, 1992, 747-752.
Optic Neuritis Study Group. Visual Function More Than 10 Years After Optic Neuritis: experience of the Optic Neuritis Treatment Trial.- Am. J. Ophthalmol., 137, 2004, 77-83.
Email this article (Login required) 
